Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families.

Read more

 
July 11, 2018
Corium Announces Issuance of Additional U.S. Patent Covering Corplex™ Donepezil Transdermal System for Alzheimer’s Disease
Second Orange Book Listable Patent Provides Expanded Coverage to 2037 MENLO PARK, Calif. , July 11, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal…


June 13, 2018
Corium Announces Issuance of Key U.S. Patent Covering Corplex™ Donepezil Transdermal System for Alzheimer’s Disease
Provides Composition of Matter Coverage to 2037 MENLO PARK, Calif. , June 13, 2018 (GLOBE NEWSWIRE) — Corium International, Inc. (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced…

OUR LEAD PRODUCT

CorplexTM Donepezil

A once-weekly treatment for Alzheimer’s disease, our lead product is a transdermal formulation of donepezil, the active ingredient in Aricept®, which is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. We have demonstrated sustained and controlled delivery of donepezil over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more

circle_couple2